Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Randomized Study Comparing JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA, Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Subjects With Relapsed and Lenalidomide-Refractory Multiple Myeloma

Next Previous
Trial Profile

A Phase 3 Randomized Study Comparing JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA, Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Subjects With Relapsed and Lenalidomide-Refractory Multiple Myeloma

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 10 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ciltacabtagene autoleucel (Primary) ; Bortezomib; Cyclophosphamide; Daratumumab; Dexamethasone; Dexamethasone; Fludarabine; Pomalidomide
  • Indications Multiple myeloma
  • Focus Registrational; Therapeutic Use
  • Acronyms CARTITUDE-4
  • Sponsors Janssen Research & Development; Janssen-Cilag

Most Recent Events

  • 03 Jun 2025 Results presented in a Janssen-Cilag Media Release.
  • 03 Jun 2025 According to Johnson & Johnson media release, data from this study was presented at the 2025 ASCO Annual Meeting evaluated PFS and OS versus standard of care in prespecified subgroups, including patients with standard and high-risk cytogenetics, extramedullary disease and by line of therapy
  • 22 May 2025 According to a Legend Biotech media release, data from this trial will be presented at the 2025 European Hematology Association's (EHA) Congress from June 12-15, 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top